We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dietary Intervention in Follicular Lymphoma (KLYMF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00455416
Recruitment Status : Unknown
Verified April 2007 by Oslo University Hospital.
Recruitment status was:  Recruiting
First Posted : April 3, 2007
Last Update Posted : May 21, 2008
University of Oslo
Information provided by:
Oslo University Hospital

Brief Summary:
A dietary intervention study in patients with Follicular Lymphoma (FL) Stage III/IV to assess the ability of several dietary factors to induce apoptosis, inhibit cell proliferation and modulate tumor cell infiltrate in vivo.

Condition or disease Intervention/treatment Phase
Follicular Lymphoma Drug: Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)) Drug: Selenium (L-Selenomethionine), Drug: Garlic extract (Allicin) Drug: Pomegranate juice (ellagic acid) Drug: Grape juice (resveratrol, quercetin) Drug: Green Tea (Epigallocathechin gallate) Phase 2

Detailed Description:
Dietary factors plays an important role in the prevention of several diseases. The cardiovascular disease mortality have dropped dramatically the last 20 years, but the relative death rates from cancer remains fairly stable. There is reason to believe that factors in the tumors microenvironment is of great importance for the outcome of many malignant diseases, including FL. Factors predicting a poor outcome are associated with inflammation, oxidative stress which both impair the hosts immune response and produces growth stimulatory signals. In this open study with 45 patients to be included we seek to perform a dietary intervention with comparison of apoptosis rate, proliferation rate and immune cell infiltrate before and after the intervention period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dietary Intervention in Stage III/IV Follicular Lymphoma. Impact on Markers of Cell Proliferation, Apoptosis, Host Immune Cell Infiltrate and Oxidative Stress.
Study Start Date : April 2007
Estimated Primary Completion Date : April 2009
Estimated Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Intervention Details:
  • Drug: Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))
    1000mgx5 daily
    Other Name: Nycoplus omega-3 1000mg
  • Drug: Selenium (L-Selenomethionine),
    100mcgx2 daily
    Other Name: Solaray selenium 100mcg
  • Drug: Garlic extract (Allicin)
    6 garlic pearls daily
    Other Name: Circuline
  • Drug: Pomegranate juice (ellagic acid)
    Pomegranate juice 100%, 660ml /495 ml every second day.
    Other Name: Produced by:Tine Meierier.
  • Drug: Grape juice (resveratrol, quercetin)
    Merlot grape juice 100%, 660ml /495 ml every second day
    Other Name: Produced by Tine Meierier
  • Drug: Green Tea (Epigallocathechin gallate)
    Green Tea. 2 cups daily
    Other Name: Green tea - twinings java green tea

Primary Outcome Measures :
  1. Apoptosis an proliferation rate in tumor cells, [ Time Frame: At the end of intervention (week 16) ]

Secondary Outcome Measures :
  1. Levels of: proinflammatory cytokines,tumor immune cell infiltrate [ Time Frame: Week 16 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or more.
  • Permanent address in Norway, located in health region south or east. People living outside these areas in other health regions in Norway may be able to participate but after individual evaluation.
  • Histologically verified follicular lymphoma grade I or II without clinical signs of transformation to aggressive lymphoma.
  • Stage III/IV.
  • Previously untreated or at least 1 year since rituximab treatment or 6 months since cytotoxic chemotherapy.
  • Not scheduled for disease specific treatment for the next 3 months.
  • At least one pathological superficial lymph node available for ultrasound guided biopsy.
  • Cytologically and/or immunocytologically compatible with follicular lymphoma.
  • Women with childbearing potential, only with use of safe contraceptives

Exclusion Criteria:

  • Gross abnormalities in blood samples. (Hematologic values Hgb< 10, leukocytes< 2,5, trombocytes <100, liver enzymes (ALAT,ASAT,GT,ALP) > 2,5 x upper normal values,bilirubin >35 creatinine >130)
  • Other serious medical illness (unstable cardiovascular disease, unstable pulmonary disease, uncontrolled diabetes, autoimmunity, chronic infection or other active cancer).
  • Use of NSAID, ASA the last two weeks prior to enrollment.
  • Use of systemic corticosteroids the last two months prior to enrollment.
  • Regular use of anticoagulants as LMW Heparin or warfarin.
  • Use of carbamazepin, nifedipin and other drugs metabolized with CYP 3A4 where interaction might cause hazardous side effects which cannot be controlled with serum measurements or organ function monitoring.
  • Inclusion in another clinical trial which involves medication or nutritional supplements.
  • Use of complementary medicine/alternative medicine which includes high dose* vitamins or antioxidants/nutritional supplements 2 weeks prior to sampling procedures .
  • Regularly use of omega 3 fatty acids more than 1g / day
  • History of serious or unstable medical or psychiatric disorder.
  • History of heavy alcohol consumption > 3 units / day.
  • Pregnancy
  • Individuals judged by the clinical investigator to be unable to follow instructions and procedures of the study.

(*high dose is defined as vitamins or antioxidant supplements exceeding what is present in regular multi-vitamin supplements covering regular RDAs)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455416

Layout table for location contacts
Contact: Kjell Magne Russnes, MD +4722934000 k.m.russnes@medisin.uio.no
Contact: Harald Jr. Holte, MD, PhD +4722934000 harald.holte@radiumhospitalet.no

Layout table for location information
RRHF RIkshospitalet Radiumhospitalet HF Recruiting
Montebello, Oslo, Norway, 0310
Contact: Kjell Magne Russnes, MD    +4722934000    k.m.russnes@medisin.uio.no   
Contact: Harald JR Holte, MD, PhD    +4722934000    harald.holte@radiumhospitalet.no   
Principal Investigator: Harald Jr Holte, Md, PhD         
Sub-Investigator: Kjell Magne Russnes, MD         
Sponsors and Collaborators
Oslo University Hospital
University of Oslo
Layout table for investigator information
Principal Investigator: Harald Jr. Holte, MD, PhD RRHF Rikshospitalet Radiumhospitalet HF
Layout table for additonal information
Responsible Party: Harald Holte MD, PhD, Rikshospitalet-Radiumhospitalet HF
ClinicalTrials.gov Identifier: NCT00455416    
Other Study ID Numbers: Dietary intervention FL
First Posted: April 3, 2007    Key Record Dates
Last Update Posted: May 21, 2008
Last Verified: April 2007
Keywords provided by Oslo University Hospital:
Low grade lymphoma
Non Hodgkin Lymphoma - Follicular Lymphoma grade 1&2 stage III/IV
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Follicular
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Trace Elements
Anti-Infective Agents
Hypolipidemic Agents
Lipid Regulating Agents
Hypoglycemic Agents
Free Radical Scavengers